UNLABELLED: Locally advanced soft-tissue sarcomas of an extremity can be treated either by amputation of the limb or by hyperthermic isolated limb perfusion (HILP) followed by resection of the tumor. In this study, the response to HILP was measured by PET with (18)F-fluorodeoxythymidine ((18)F-FLT). METHODS: Ten patients with primary nonresectable soft-tissue sarcomas of an extremity underwent HILP with tumor necrosis factor-alpha and melphalan. Before and after HILP, all patients underwent PET with (18)F-FLT for response evaluation. RESULTS: Before HILP, all tumors were clearly visible on (18)F-FLT PET; for the maximum standardized uptake value (SUV(max)), the mean was 3.5 (range, 1.0-6.7), and for the mean standardized uptake value (SUV(mean)), the mean was 1.9 (range, 0.7-2.7). After HILP, all but 1 tumor showed necrosis ranging from 10% to 95%. (18)F-FLT PET after HILP revealed significantly decreased uptake of the tracer. The mean SUV(max) decreased to 1.7 (P = 0.008), and the mean SUV(mean) decreased to 0.8 (P = 0.002). One small axillary lymph node metastasis was not visible on (18)F-FLT PET. CONCLUSION: (18)F-FLT PET revealed high uptake in soft-tissue sarcomas. (18)F-FLT uptake was correlated with the mitotic index of the tumors (r = 0.82 and P = 0.004 for SUV(max); r = 0.87 and P = 0.001 for SUV(mean)). After HILP, the uptake of (18)F-FLT decreased significantly (P = 0.008 and P = 0.002 for SUV(max) and SUV(mean), respectively). Tumors with initially high (18)F-FLT uptake showed a better response to HILP (r = 0.64, P < 0.05). Software fusion of PET images with images from conventional imaging modalities revealed the heterogeneity of the tumors before and after HILP. Such data can help a surgeon in planning the resection of a tumor.
UNLABELLED: Locally advanced soft-tissue sarcomas of an extremity can be treated either by amputation of the limb or by hyperthermic isolated limb perfusion (HILP) followed by resection of the tumor. In this study, the response to HILP was measured by PET with (18)F-fluorodeoxythymidine ((18)F-FLT). METHODS: Ten patients with primary nonresectable soft-tissue sarcomas of an extremity underwent HILP with tumor necrosis factor-alpha and melphalan. Before and after HILP, all patients underwent PET with (18)F-FLT for response evaluation. RESULTS: Before HILP, all tumors were clearly visible on (18)F-FLT PET; for the maximum standardized uptake value (SUV(max)), the mean was 3.5 (range, 1.0-6.7), and for the mean standardized uptake value (SUV(mean)), the mean was 1.9 (range, 0.7-2.7). After HILP, all but 1 tumor showed necrosis ranging from 10% to 95%. (18)F-FLT PET after HILP revealed significantly decreased uptake of the tracer. The mean SUV(max) decreased to 1.7 (P = 0.008), and the mean SUV(mean) decreased to 0.8 (P = 0.002). One small axillary lymph node metastasis was not visible on (18)F-FLT PET. CONCLUSION: (18)F-FLT PET revealed high uptake in soft-tissue sarcomas. (18)F-FLT uptake was correlated with the mitotic index of the tumors (r = 0.82 and P = 0.004 for SUV(max); r = 0.87 and P = 0.001 for SUV(mean)). After HILP, the uptake of (18)F-FLT decreased significantly (P = 0.008 and P = 0.002 for SUV(max) and SUV(mean), respectively). Tumors with initially high (18)F-FLT uptake showed a better response to HILP (r = 0.64, P < 0.05). Software fusion of PET images with images from conventional imaging modalities revealed the heterogeneity of the tumors before and after HILP. Such data can help a surgeon in planning the resection of a tumor.
Authors: Sasan Partovi; Andres A Kohan; Lisa Zipp; Peter Faulhaber; Christos Kosmas; Pablo R Ros; Mark R Robbin Journal: Int J Clin Exp Med Date: 2014-03-15
Authors: Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; Sarah M Dry; Piriya Sutthiruangwong; Claudio Spick; Caius Radu; Wolfgang A Weber; William D Tap; Fritz C Eilber Journal: Cancer Date: 2011-10-21 Impact factor: 6.860
Authors: Rajen J Mody; Chuong Bui; Raymond J Hutchinson; Greg A Yanik; Valerie P Castle; Kirk A Frey; Barry L Shulkin Journal: Pediatr Blood Cancer Date: 2010-02 Impact factor: 3.167
Authors: Dimosthenis Andreou; Henrike Boldt; Daniel Pink; Björn Jobke; Mathias Werner; Markus Schuler; Peter Reichardt; Per-Ulf Tunn Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-12 Impact factor: 9.236
Authors: A C M van de Luijtgaarden; J W J de Rooy; L F de Geus-Oei; W T A van der Graaf; W J G Oyen Journal: Cancer Imaging Date: 2008-10-04 Impact factor: 3.909
Authors: Benjamin Schwindenhammer; Lars Erik Podleska; Andrea Kutritz; Sebastian Bauer; Sien-Yi Sheu; Georg Taeger; Kurt Werner Schmid; Florian Grabellus Journal: World J Surg Oncol Date: 2013-08-12 Impact factor: 2.754